Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study

Article information

Intest Res. 2023;21(2):273-273

Publication date (electronic) : 2023 April 28

doi : https://doi.org/10.5217/ir.2021.00173.e

Kyunghwan Oh ¹, Hee Seung Hong ¹, Nam Seok Ham ¹, Jungbok Lee ², Sang Hyoung Park ¹^,³^,⁴, Suk-Kyun Yang ¹^,³^,⁴, Hyuk Yoon ⁵, You Sun Kim ⁶, Chang Hwan Choi ⁷, Byong Duk Ye ¹^,³^,⁴, on behalf of the Korean Association for the Study of Intestinal Diseases

¹Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

²Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

³Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

⁴Digestive Diseases Research Center, University of Ulsan College of Medicine, Seoul, Korea

⁵Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

⁶Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea

⁷Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea

https://doi.org/10.5217/ir.2021.00173

Intest Res 2023;21(1):137-147

In the article entitled “Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study,”1 the data on page 140 of the text were incorrectly indicated. The revised data are shown in bold.

“Corticosteroid-free clinical remission/response were achieved in 25 (51.0%)/29 (59.2%) patients at week 8 and 26 (53.1%)/34 (69.4%) patients at week 20, respectively (Fig. 2).”

References

1. Oh K, Hong HS, Ham NS, et al. Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study. Intest Res 2023;21:137–147.

Article information Continued

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.